The study includes Rochester Epidemiology Project data from 7,044 adult stroke survivors collected between January 2000 and June 2022, according to a Nov. 11 news release from the American Heart Association.
Rochester, Minn.-based Mayo Clinic researchers analyzed the effect GLP-1s and SGLT2s medications had on stroke survivors’ risk of a second stroke, heart attack or death.
FDA approved medications included in the study were GLP-1s liraglutide, semaglutide and tirzepatide, and SGLT2s canagliflozin, dapagliflozin, empagliflozin and ertugliflozin.
Here are five things to know from the study:
- Adults who took either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of heart attack.
- Adults who took an SGLT2 had a 67% lower risk of having a subsequent stroke.
- The death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11.8%, compared to 54% among patients who did not take either medication.
- The heart attack rate among stroke survivors who took either a GLP-1 or an SGLT2 was 1.5%, compared to 6.1% among patients who did not take either medication.
- The rate of second stroke was approximately 6% among stroke survivors regardless of whether they took a GLP-1 or an SGLT2 medication.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
